Last reviewed · How we verify

NCT03880162: CaPrO

Metabolic Effects of a Low Carbohydrate Versus a Standard Diet in Morbidly Obese With Prediabetes

Completed NA Last updated 9 December 2024
What this trial tests

NA trial testing Low carbohydrate diet in PreDiabetes in 20 participants. Completed in 3 May 2024.

Timeline
13 May 2019
Primary endpoint
3 May 2024
3 May 2024

Quick facts

Lead sponsorInsel Gruppe AG, University Hospital Bern
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment20
Start date13 May 2019
Primary completion3 May 2024
Estimated completion3 May 2024
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

18 and older, any sex, with PreDiabetes or Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the metabolic effects of a low carbohydrate versus energy-matched standard diet in morbidly obese individuals with prediabetes awaiting bariatric surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Taxonomic and functional shifts in the microbiome of severely obese, prediabetic patients: Ketogenic diet versus energy-matched standard diet.
    Stone J, Tripyla A, Scalise MC, Balmer ML, et al · · 2026 · cited 1× · PMID 41395693 · DOI 10.1111/dom.70364

Verify or expand the search:

Other trials of Low carbohydrate diet

Trials testing the same drug.

Other recruiting trials for PreDiabetes

Currently open trials in the same condition.

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing